P2.06-12 The Safety and Efficacy of Durvalumab as 1st Line Therapy in Patients with Advanced NSCLC and ECOG PS of 2
Shaverdashvili, K., Reyes, V., Wang, H., Mehta, D., Marsh, C., Waas, J.K., VanderWeele, R.A., Peracha, S.M., Liang, H., Gerber, D.E., Dowell, J., Villaruz, L.C.
Published in Journal of thoracic oncology (01.11.2023)
Published in Journal of thoracic oncology (01.11.2023)
Get full text
Journal Article
FP14.06 Multicenter Analysis of Mechanisms of Resistance to Osimertinib (O) in EGFR Mutated NSCLC: An ATOMIC Registry Study
Bauml, J.M., Mick, R., Mccoach, C., Weiss, J., Marrone, K., Nieva, J., Villaruz, L., Levy, B., Moreno, R., Murkherji, R., Sun, F., Schwartzman, W., Shaverdashvili, K., Wang, X., Shah, M., Woodley, J., Miller, N., Succe, C., Ullah, T., Lovly, C., Doebele, R., Iams, W., Horn, L., Dowell, J., Liu, G., Leighl, N., Patil, T., Liu, S., Velcheti, V., Aisner, D., Camidge, R.
Published in Journal of thoracic oncology (01.03.2021)
Published in Journal of thoracic oncology (01.03.2021)
Get full text
Journal Article